Does ferritin tell me anything about hepatic fat on tirzepatide?

What I have: ferritin · tirzepatide.

I want to know whether this is a real physical effect or an artefact of how it is measured.

What prompted the question is an inconsistency between two sources I otherwise trust.

Why does this happen, and what would falsify the usual explanation?

The relevant caution is that a rapid rise, particularly with bilirubin, is a different event from a stable mild elevation and needs handling differently.

Creatine kinase, alkaline phosphatase and bilirubin together tell you which compartment the abnormality is in, and ordering the transaminases alone throws that information away.

The part that matters: alanine aminotransferase is relatively liver-specific; aspartate aminotransferase is also present in muscle, heart and red cells. A raised AST with a normal ALT after heavy resistance training is usually muscle, and creatine kinase settles the question.

Laboratory-specific reference intervals for transaminases vary enough that cross-laboratory comparison of borderline values is unreliable.

Nothing here is medical advice. An abnormal result needs somebody who can take a history and examine you.

Get a baseline before you start anything, because it converts an uninterpretable result into an interpretable one for the cost of one blood draw.

edited 8 Jan 2026 by Dr_Idris_Coulibaly — added the method parameters

Before attributing anything to a compound, account for alcohol, muscle injury from new training, and any over-the-counter product being taken alongside.

Gamma-glutamyl transferase is sensitive and unspecific: it rises with alcohol, with several medications and with fatty liver, and an isolated elevation rarely changes anything on its own.

The underlying point is that an isolated result three weeks after starting anything is difficult to interpret. A baseline taken before starting makes the same result trivially interpretable, which is the argument for baselines.

Hy's law and its variants are the standard framework for identifying drug-induced liver injury in trials and are why bilirubin is measured alongside transaminases rather than instead.

Research-use material of unknown content is an unquantifiable variable in any such attribution.

Read the pattern before the magnitude, and the magnitude in multiples of the upper limit.

The honest answer is that mild elevation is very common, that it usually improves with weight loss, and that the exceptions are the reason anyone checks.

Weight loss of ten per cent or more typically reduces transaminases substantially in people whose elevation was driven by hepatic fat, which is the majority of mild elevations in this population.

Population data show a substantial fraction of adults with mild transaminase elevation attributable to hepatic steatosis, which sets the base rate against which any new finding should be read.

Attributing an enzyme change to a compound requires a baseline, and most people asking have not got one.

Isolated mild elevation is common and usually improves with weight loss.

Answering this needs the magnitude in multiples of the upper reference limit, because the thresholds that matter clinically are defined that way and not in absolute units.

Very rapid weight loss can transiently worsen liver biochemistry, which is one of several arguments against pursuing the steepest possible trajectory.

The caveat is direct: rising liver enzymes with jaundice, dark urine or right-upper-quadrant pain is a same-day clinical problem, not a forum question.

Transaminases plus bilirubin plus alkaline phosphatase, or you have not measured enough to conclude anything.